Wednesday - May 14, 2025
SAN DIEGO / Oct 28, 2024 / Business Wire / QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team will attend three upcoming investor conferences and participate in fireside chats at all three conferences.
UBS Global Healthcare Conference
On Tuesday, November 12, 2024, QuidelOrtho is scheduled to participate in a fireside chat at 2:00 p.m. ET / 11:00 a.m. PT at the conference in Rancho Palos Verdes, California.
Citi 2024 Global Healthcare Conference
On Wednesday, December 4, 2024, QuidelOrtho is scheduled to participate in a fireside chat at 1:00 p.m. ET / 10:00 a.m. PT at the conference in Miami, Florida.
Evercore ISI 7th Annual HealthConX Conference
On Thursday, December 5, 2024, QuidelOrtho is scheduled to participate in a fireside chat at 10:00 a.m. ET / 7:00 a.m. PT at the conference in Coral Gables, Florida.
Interested parties can access the live webcasts and replays of the events in the “Events & Presentations” section of the “Investor Relations” page of QuidelOrtho’s website at https://ir.quidelortho.com/.
QuidelOrtho is dedicated to advancing diagnostics to power a healthier future. For more information, please visit quidelortho.com and follow QuidelOrtho on LinkedIn, Facebook and X.
About QuidelOrtho Corporation
QuidelOrtho Corporation (Nasdaq: QDEL) is a world leader in in vitro diagnostics, developing and manufacturing intelligent solutions that transform data into understanding and action for more people in more places every day.
Offering industry-leading expertise in immunoassay and molecular testing, clinical chemistry and transfusion medicine, bringing fast, accurate and reliable diagnostics when and where they are needed – from home to hospital, lab to clinic. So that patients, clinicians and health officials can spot trends sooner, respond quicker and chart the course ahead with accuracy and confidence.
Building upon its many years of groundbreaking innovation, QuidelOrtho continues to partner with customers across the healthcare continuum and around the globe to forge a new diagnostic frontier. One where insights and solutions know no bounds, expertise seamlessly connects and a more informed path is illuminated for each of us.
Last Trade: | US$35.51 |
Daily Change: | -1.91 -5.10 |
Daily Volume: | 2,918,348 |
Market Cap: | US$2.390B |
March 10, 2025 February 12, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load